 |
1 Disease |  |
23 Trials |
|
23 Trials |  |
185 News |  |
| «123 |
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 29, 2016
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Jun 13, 2016
P3, N=519, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Apr 20, 2016
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Sep 2015
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial suspension, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 23, 2016
P1, N=28, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> Sep 2015 Recruiting --> Suspended
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment change, Combination therapy, Metastases: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Dec 31, 2015
P1/2, N=69, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=95 --> 69
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 30, 2015
P3, N=523, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=95 --> 69 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 22, 2015
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Nov 10, 2015
P1, N=6, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2016 N=33 --> 6 | Trial primary completion date: Sep 2015 --> May 2015
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=345, Recruiting, Sponsor: National Cancer Institute (NCI)
N=33 --> 6 | Trial primary completion date: Sep 2015 --> May 2015 Suspended --> Recruiting
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 24, 2015
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2016
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 21, 2015
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Jun 2015 --> Dec 2015
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=300, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: May 2015 --> Jan 2018
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> Jan 2018 Trial primary completion date: Jun 2015 --> Sep 2015
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=300, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Sep 2015 Recruiting --> Suspended
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - May 19, 2015
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Suspended --> Active, not recruiting
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Mar 9, 2015
P1, N=33, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jun 2015
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial suspension: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Sep 22, 2014
P1, N=33, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Suspended
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 8, 2014
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 5, 2014
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - May 18, 2014
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Dec 2014
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Mar 10, 2014
P3, N=519, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy, Metastases: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=95, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial, IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Jan 27, 2014
P3, N=519, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 22, 2014
P3, N=523, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 5, 2014
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 4, 2013
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 27, 2013
P3, N=523, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Jul 2013 --> Oct 2013
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Aug 29, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Jun 27, 2013
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jun 24, 2013
P3, N=523, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Rituxan (rituximab) / Roche
New P2 trial: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - May 15, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Apr 9, 2013
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
New P1 trial, Combination therapy: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 26, 2012
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)